All In Biotech

Drug Trial Radar · NCT02200770

N-MOmentum: A Clinical Research Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorders

A Double-masked, Placebo-controlled Study With Open-label Period to Evaluate the Efficacy and Safety of MEDI-551 in Adult Subjects With Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders.

Last checked: Nov 20, 2026Latest source record: Dec 3, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 231 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

231

Actual

Start

Apr 1, 2015

Primary completion

Oct 26, 2018

Study completion Nov 6, 2020

Sponsor

Lead sponsor
MedImmune LLCAstraZeneca (AZN)
Sponsor type
Industry
First posted
Jul 25, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To compare the efficacy of inebilizumab (MEDI-551) versus placebo in reducing the risk of an neuromyelitis optica/neuromyelitis optica- spectrum disorders (NMO/NMOSD) attack in participants with NMO/NMOSD.

Conditions

  • Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders

Interventions

  • InebilizumabDrug

    Participants will receive IV inebilizumab 300 mg.

  • PlaceboOther

    Participants will receive IV placebo matched to inebilizumab.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to Adjudication Committee (AC)-Determined Neuromyelitis Optica Spectrum Disorder (NMOSD) Attack During RCPTime frame: Day 1 (Baseline) through Day 197

Locations

98 sites in 25 countries. Site status is shown where the registry gives one.

  • Research Site

    Birmingham, Alabama

  • Research Site

    Sacramento, California

  • Research Site

    San Francisco, California

  • Research Site

    Aurora, Colorado

  • Research Site

    New Haven, Connecticut

  • Research Site

    Maitland, Florida

  • Research Site

    Chicago, Illinois

  • Research Site

    Kansas City, Kansas

  • Research Site

    Baltimore, Maryland

  • Research Site

    Detroit, Michigan

  • Research Site

    Rochester, Minnesota

  • Research Site

    St Louis, Missouri

  • Research Site

    Raleigh, North Carolina

  • Research Site

    Cincinnati, Ohio

  • Research Site

    Cleveland, Ohio

  • Research Site

    Mansfield, Ohio

  • Research Site

    Dallas, Texas

  • Research Site

    Houston, Texas

  • Research Site

    Richmond, Virginia

  • Research Site

    Melbourne, Australia

  • Research Site

    Sofia, Bulgaria

  • Research Site

    Sofia, Bulgaria

  • Research Site

    Sofia, Bulgaria

  • Research Site

    Varna, Bulgaria

  • Research Site

    Vancouver, British Columbia, Canada

  • Research Site

    Barranquilla, Colombia

  • Research Site

    Bogotá, Colombia

  • Research Site

    Bogotá, Colombia

  • Research Site

    Cali, Colombia

  • Research Site

    Olomouc, Czechia

  • Research Site

    Prague, Czechia

  • Research Site

    Teplice, Czechia

  • Research Site

    Tallinn, Estonia

  • Research Site

    Tartu, Estonia

  • Research Site

    Berlin, Germany

  • Research Site

    Dresden, Germany

  • Research Site

    Düsseldorf, Germany

  • Research Site

    Leipzig, Germany

  • Research Site

    Münster, Germany

  • Research Site

    Rostock, Germany

Showing 40 of 98 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.